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Large animal modelIn humans, chronic infection with the gammaherpesvirus Epstein–Barr virus is usually asymptomatic; how-
ever some infected individuals develop hematological and epithelial malignancies. The exact role of EBV in
lymphomagenesis is poorly understood partly because of the lack of clinically relevant animal models.
Here we report the detection of serological responses against EBV capsid antigens in healthy dogs and
dogs with spontaneous lymphoma and that dogs with the highest antibody titers have B cell lymphoma.
Moreover, we demonstrate the presence of EBV-like viral DNA and RNA sequences and Latent Membrane
Protein-1 in malignant lymph nodes of dogs with lymphoma. Finally, electron microscopy of canine malig-
nant B cells revealed the presence of classic herpesvirus particles. These ﬁndings suggest that dogs can be
naturally infected with an EBV-like gammaherpesvirus that may contribute to lymphomagenesis and that
dogs might represent a spontaneous model to investigate environmental and genetic factors that inﬂuence
gammaherpesvirus-associated lymphomagenesis in humans.
© 2012 Elsevier Inc. All rights reserved.Background
EBV is the prototypical, double stranded DNA gammaherpes-
virus (GHV) that belongs to the lymphocryptovirus (LCV) subfam-
ily (Bajaj et al., 2007). As one of the most prevalent viral infections
known, EBV infects up to 90% of the human population (Young
and Rickinson, 2004). Following acute infection, viral latency is
established within the B cell compartment and in the majority of
immune-competent individuals chronic infection is asymptomatic
(Callan et al., 1998; Munz et al., 2000; Rickinson and Moss,
1997). However, a subset of infected individuals develop EBV asso-
ciated malignancies that reﬂect the restricted cellular tropism of
EBV. These include hematological malignancies such as Hodgkin's
lymphoma (HL), non-Hodgkin's lymphoma (NHL) (including Bur-
kitt's lymphoma (BL), diffuse large B cell lymphoma (DLBCL) and
NK/T cell lymphoma), post transplant lymphomas and epithelialia School of Veterinary Medi-
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rights reserved.malignancies including nasopharyngeal and gastric carcinoma
(Crawford, 2001; Kutok and Wang, 2006; Young and Murray,
2003). Despite intense study and the recognition that EBV proteins
activate intracellular signaling pathways that are associated with
oncogenesis (Middeldorp, 2003; Rowe, 1994; Sivachandran,
2010), the exact mechanisms by which EBV contributes to the
pathogenesis of lymphoid and epithelial neoplasms are not
completely understood, thus hindering the development of effec-
tive strategies to treat or prevent EBV associated neoplasia
(Epstein and Barr, 1964; Thorley-Lawson and Allday, 2008). One
of the primary obstacles to understanding the pathogenesis of
EBV associated disease is the lack of a clinically relevant spontane-
ous animal model in which concurrent genetic and environmental
factors thought to be necessary for virus-associated lymphomagen-
esis are recapitulated.
The domestic dog shares a close phylogenetic relationship with
humans and has co-habited with them for 15,000 years (Lindblad-
Toh et al., 2005; Sampson, 2006; Vila et al., 1997). As both genetic
and environmental factors inﬂuence the initiation and progression
of malignancy, it is not surprising that dogs develop spontaneous
lymphoid malignancies including DLBCL and Burkitt-like lymphoma
that share remarkable similarities in biological, behavioral, genetic
and cytogenetic characteristics with their counterpart subtypes in
humans (Breen and Modiano, 2008; Vail and MacEwen, 2000). For
example, a chromosomal translocation observed in human BL that
places MYC under the control of the IgH promoter, leading to
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associated lymphomagenesis, is also observed in canine DLBCL and
Burkitt-like lymphoma (Breen and Modiano, 2008; Dalla-Favera et
al., 1982; Taub et al., 1982). In addition, the canonical NF-κB pathway
is constitutively active in malignant lymphocytes of dogs with DLBCL
(Gaurnier-Hausser et al., 2011), a ﬁnding that is shared with EBV-
associated lymphoid malignancies in humans. Indeed, c-myc and
NF-κB are the two main transcription factors activated in the latency
III phase of EBV infection and they mediate the biological characteris-
tics of EBV transformed cells (Faumont et al., 2009). Currently, there
are no recognized gammaherpesviruses that infect dogs. However,
previous studies have revealed that following transfection with
human CD21, the receptor for EBV, canine epithelial cells (Mardin
Darby Canine Kidney (MDCK)) can be infected with EBV and sustain
infection to establish stable EBV-infected canine clones (Chodosh
et al., 2000; Yates et al., 1985). In these cells, the viral genome exists
as an episome and a latency type III gene transcription proﬁle is
expressed (Yang et al., 2000). Furthermore, antibodies to an EBV-
like virus and EBV-like DNA sequences have been identiﬁed in
serum samples and peripheral blood lymphocytes respectively of
healthy pet dogs (Chiou et al., 2005; Milman et al., 2011). These ﬁnd-
ings suggest that an EBV-like gammaherpesvirus can naturally infect
dogs and similar to the majority of humans infected with EBV, infec-
tion is asymptomatic.
Here we have investigated the hypotheses that pet dogs can be
infected with an EBV-like herpesvirus and that this virus contrib-
utes to spontaneous B cell lymphoma in this species. We have
detected serological responses against two EBV-viral capsid anti-
gens (VCA) in privately owned dogs and have found that dogs
with the highest VCA-IgG titers have spontaneous B cell lympho-
ma. Moreover, we show by in situ hybridization (ISH) and PCR
that viral nucleotide sequences with high homology to EBV are
present within the malignant lymph nodes of dogs with DLBCL
and that Latent Membrane Protein-1 (LMP-1), a major oncogenic
protein of EBV, is expressed in the lymph nodes of some dogs
with B cell lymphoma. Finally, we show the presence of classic
herpesvirus particles in cultured malignant canine B cells using
electron microscopy. Taken together, these ﬁndings raise the in-
triguing possibility that the domestic dog might serve as a long
sought-after, spontaneous, large animal model in which to investi-
gate EBV-associated lymphomagenesis and the environmental and
genetic factors that inﬂuence tumor initiation and progression. Fur-
thermore, our results begin to provide valuable insight into poten-
tial mechanisms of lymphomagenesis in the dog and pave the way
toward development of a clinically relevant spontaneous model in
which to determine the safety and efﬁcacy of novel therapies for
the treatment and prevention of EBV-associated lymphomas.Fig. 1. Detection of VCA-p18 speciﬁc IgG responses in dogs. A. Plasma samples from 41 non-
VCA-p18 antigen by ELISA. Relative optical density (O.D.) results were determined by dividin
sample. B. Plasma samples from 21 dogs with B cell lymphoma and 5 dogs with T cell lymph
results are shown. C. Plasma samples from 2 dogs with lymphoma and human positive and
ELISA (*, pb0.05, Student's t-test).Results
Serological evidence of infection with an EBV-related gammaherpesvirus
in domestic dogs
To test the hypothesis that dogs are naturally infected with an
EBV-related herpesvirus, we evaluated plasma samples from 41
dogs without lymphoma and 48 dogs with spontaneous lymphoma
for the presence of IgG antibodies against the highly immunogenic,
lytic phase, small VCA p18 encoded by reading frame BFRF3, by
ELISA (van Grunsven et al., 1993a, 1993b). Thirty-six different dog
breeds were represented in the analysis with mixbreeds, Golden Re-
trievers, Labradors and Miniature Schnauzers over-represented in
the sampled population. Golden Retrievers, Labradors and Miniature
Schnauzers were also over-represented in the lymphoma group. Mix-
breeds were over-represented in the non-lymphoma group. ELISA
revealed a scattered dataset with the relative O.D. of samples from
8/48 dogs with lymphoma and 3/41 dogs without lymphoma higher
than that of the human positive control (Fig. 1A). There was no appar-
ent breed pre-disposition to high anti-VCA-p18 titers. Dogs with high
anti-VCA-p18 titers in the lymphoma group included 2 mixbreeds, 1
Labrador, 1 Golden Retriever, 1 Miniature Schnauzer, 1 Malamute, 1
English Setter and 1 Bichon Frise. Dogs with high anti-VCA-p18 titers
in the non-lymphoma group included 1 mixbreed, 1 Golden Retriever
and 1 Miniature Schanuzer. These ﬁndings indicate that a subset of
non-lymphoma dogs and dogs with lymphoma have generated anti-
body responses against EBV VCA p18. End-point dilution titers of
dogs with lymphoma in this dataset ranged from b1:64 to 1:32,768
and in non-lymphoma dogs ranged from b1:64 to 1:512. Plasma sam-
ples taken from 34 adult SPF beagles were also evaluated and 32/34
dogs had end point dilution titers b1:64. Although end-point dilution
antibody titers of both cohorts of privately owned dogs varied, those
dogs with the highest VCA-p18 speciﬁc end-point dilution titers were
dogs with spontaneous lymphoma (Fig. 1A). Furthermore, when the
relative O.D. of samples from this group of dogs with known lympho-
ma immunophenotype (B cell: 21/48, T cell 5/48) were analyzed, the
highest relative O.D. values were found in dogs with B cell lymphoma
(Fig. 1B).
To conﬁrm the speciﬁcity of VCA-p18 reactivity in this assay, plas-
ma samples from 2 dogs with B cell lymphoma and high anti-VCA-
p18 IgG titers were pre-incubated with VCA-p18 antigen. This was
done to occupy p18 speciﬁc antigen binding sites of antibodies in
plasma samples and therefore demonstrate the speciﬁcity of ELISA
for p18 protein. In both samples, pre-incubation with VCA-p18 signif-
icantly reduced the O.D. reading of the samples indicating that
detected antibody responses were speciﬁc for VCA-p18 in these
dogs (Fig. 1C). Similar blocking led to a signiﬁcant reduction inlymphoma dogs and 48 dogs with lymphoma were evaluated for IgG responses against
g the average sample O.D. by the average O.D. of a single, constant seronegative human
oma were evaluated for IgG responses against VCA-p18 antigen by ELISA. Relative O.D.
negative control samples were blocked with VCA-p18 antigen prior to evaluation by
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negative human control. Conversely, boiling p18 antigen prior to its
use as the target antigen in ELISA had no effect on the O.D. readings
suggesting that, as in humans, canine IgG antibodies generated
against VCA-p18 are most likely speciﬁc for linear epitopes within
VCA-p18 (data not shown) (van Grunsven et al., 1994).
In addition to VCA-p18 seropositivity, serological responses di-
rected against p23, another small VCA encoded by the BLRF2 reading
frame have been reported as highly speciﬁc indicators of EBV infec-
tion in humans (Reischl et al., 1996). To determine whether dogs
have detectable IgG responses against EBV VCA-p23 and whether
these responses correlate with antibody responses against VCA-p18,
plasma from 25 dogs with spontaneous lymphoma (evaluated in
Fig. 1A) were evaluated for p23 immunoreactivity by ELISA. ELISA re-
sults revealed a scattered distribution of data points that correlated
signiﬁcantly with anti-VCA-p18 IgG responses in this group of dogs
(R2=0.817) (Fig. 2A).
To conﬁrm the speciﬁcity of canine antibody responses for VCA-
p23, Western blot analysis was performed using puriﬁed VCA-p23 an-
tigen to detect the presence of VCA-p23 speciﬁc IgG responses in
dogs. Plasma samples from 4 dogs with B cell lymphoma and high
anti-VCA-p23 relative O.D.s and two healthy non-lymphoma dogs
with low anti-VCA-p23 relative O.D.s were evaluated. Seropositive
human plasma was used as a positive control (Fig. 2B). Bands of
~8 kDa and 18 kDa were identiﬁed in human seropositive plasma
and plasma from dogs with B cell lymphoma. In contrast, no activity
was identiﬁed in either of the healthy non-lymphoma dogs analyzed.
These results indicate that IgG responses speciﬁc for VCA-p23 antigen
can be detected in domestic dogs and that these responses correlate
with antibody responses speciﬁc for VCA-p18 antigen. These data
suggest that a subpopulation of domestic dogs have developed immu-
nological responses against two well-characterized and highly specif-
ic GHV associated VCAs and support the hypothesis that pet dogs can
be naturally infected with an EBV-like gammaherpesvirus.
Indirect immunoﬂuorescence detects seropositivity in dogs with high
VCA-p18 antibody titers
The gold standard for serological diagnosis of EBV infection re-
mains the indirect IgG immunoﬂuorescence assay (IFA) that detects
antibodies directed against clusters of Early Antigen (EA), EBNA1
and VCA antigens expressed by EBV-transformed lymphoblasts
(Henle et al., 1974). As these tests are labor intensive and subjective
they have largely been replaced by ELISA assays. However, they are
still useful in validating ELISA results (Klutts et al., 2009). Therefore
to conﬁrm the presence of serological responses directed against
EBV-like viral proteins in dogs, IFA was performed using EBV- trans-
formed lymphoblastoid cell lines as targets and plasma from 3 dogsFig. 2. Detection of VCA-p23 speciﬁc IgG responses in dogs. A. Plasma samples from 25 dogs
A correlative analysis of O.D. of the VCA-p18 and VCA-p23 speciﬁc IgG responses as determi
in dog plasma. Each strip contains recombinant VCA-p23 antigen. Strips were incubatedwith p
dogs with low anti-p18/p23 IgG titers as indicated. Human EBV seropositive and seronegativewith lymphoma and high VCA-p18 titers and 1 healthy, non-
lymphoma dog with a low VCA-p18 titer. Results were compared to
human positive and negative serological controls. In 2 dogs with
high VCA-p18 antibody titers, bright, granular, primarily cytoplasmic
ﬂuoresence was present and comparable with the human positive se-
rological control. In contrast, plasma from the healthy non-lymphoma
dog with a low VCA-p18 titer showed no increase in immunoﬂuores-
cence above the human negative control (Fig. 3).
Detection of herpes-like viral DNA sequences in malignant lymph nodes
of dogs with spontaneous B cell lymphoma
The results of our serological studies suggest that domestic dogs
may be infected with an EBV-related GHV and that those dogs with
the highest anti-VCA IgG titers have spontaneous lymphoma. Based
on these results we hypothesized that infection with an EBV-like
GHV may contribute to lymphomagenesis in the domestic dog. In
humans, the detection of virus-speciﬁc sequences within lymphoid
malignancies is used to indicate an association between viral infec-
tion and oncogenesis. Therefore, we sought to determine whether
herpesvirus DNA sequences were present in malignant lymphocytes
of dogs with DLBCL. We performed PCR using previously described
degenerate primers that amplify a highly conserved region in the
DNA polymerase gene of the herpesviridae family (Rose et al.,
1997). RNA was extracted from the cryopreserved malignant lymph
nodes of three dogs with DLBCL and lymph nodes from three healthy
dogs. cDNA generated using random hexamers was used as template
DNA in the reaction. An initial PCR product of approximately 536 bp
was obtained from control LCL cDNA (Fig. 4A). No clear amplicons
were identiﬁed in either the lymph nodes of the 3 dogs with DLBCL,
the 3 healthy control dogs, or in a water only control. The presence
of cDNA within all samples was conﬁrmed by PCR ampliﬁcation of
cyclophilin (Fig. 4B). PCR using previously described degenerate
nested primers and the ampliﬁed products as a template produced a
~250 bp product in dog 083-001 only (data not shown). The expected
size of the nested product of the target herpesvirus DNA polymerase
is 236 bp (Rose et al., 1997). The DNA sequence of the ampliﬁed
250 bp PCR product showed high sequence homology with the
BALF5 gene of EBV that encodes the viral DNA polymerase in the 5′
region with disparity in the 3′ region. Additional nested primers
were designed against the canine sequence in the conserved 5’ se-
quence and in the disparate 3′ sequence that would yield a product
of 150 bp. These nested primers were used following the ﬁrst round
PCR ampliﬁcation to determine whether this viral DNA polymerase
sequence could be detected in additional lymphoma samples. Nested
PCR using primers designed on the canine sequence was performed
on the ﬁrst round PCR product (shown in Fig. 4A). Amplicons of
~150 bp were identiﬁed in two of the dogs with DLBCL (includingwith lymphoma were evaluated for IgG responses against VCA-p23 antigen by ELISA .
ned by ELISA is shown. B. Western blot analysis of antibodies to recombinant VCA-p23
lasma from 4 dogswith lymphoma and high anti-p18/p23 IgG titers and 2 non-lymphoma
plasma were used as controls.
Fig. 3. Indirect immunoﬂuorescence conﬁrms seropositivity in dogs with high anti-
VCA-p18 IgG titers. Indirect immunoﬂuorescence was performed on canine plasma
samples using human lymphoblastoid cells as targets. Bound IgG was detected using
a FITC conjugated rabbit anti-canine IgG. A. Positive control using human EBV-
positive serum. B. Negative control using non-reactive human serum. C. Plasma from
a dog with a 1:32,768 anti-VCA-p18 IgG titer and B cell lymphoma. Results are repre-
sentative of 2/3 dogs with high anti-VCA-p18 IgG titers D. Plasma from a healthy,
non-lymphoma dog with a low anti-VCA-p18 IgG titer.
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produced amplicons in the LCL control. Amplicon nucleotide se-
quences were almost identical between the two dogs and showed
disparity compared to the EBV sequence in the 3’ region as identiﬁed
using the original nested PCR primers (Fig. 4D). ORF translation of the
sequenced products showed high homology to the EBV BALF5 protein
(Fig. 4E). A BLAST search of the translated amino acid sequence
revealed that it is most closely related to human herpesvirus 4
(EBV). Furthermore, minimal sequence homology was found with
the cloned sequence of canine herpesvirus-1 (CHV-1) DNA polymer-
ase (Fig. 4F; GenBank Accession No. EU531507) indicating that the
ampliﬁed viral sequence does not reﬂect infection with CHV-1.
To determine whether additional EBV-like sequences were pre-
sent in malignant canine lymph node tissue, we performed PCR for
EBNA3C on genomic DNA isolated from the malignant lymphocytesFig. 4. Detection of EBV-like DNA polymerase sequences in pet dogs with spontaneous B cell
on cDNA synthesized from lymph nodes and used in A. C. Nested PCR reaction performed
sequence. D. Nucleotide sequences of nested PCR amplicons and alignment to EBV DNA poly
ucts and alignment with EBV DNA polymerase protein. F. ORF translation of nested PCR pro
No: EU31507); 083-001, 083-004 and 083-009 samples from dogs with B cell lymphoma; Nof 9 dogs with conﬁrmed B cell lymphoma. EBNA3C is one of six nu-
clear proteins that is expressed during latent EBV infection and unlike
DNA polymerase it lacks homology with genes from any other human
herpesvirus (Sample, 1990). Samples from three dogs (083-001, 083-
004 and 083-009) yielded amplicons of approximately 150 bp, the
expected product size of EBV-1 (Moon et al., 2004) (Fig. 5A). Nucleo-
tide sequences of these amplicons revealed high sequence homology
with EBNA3C (Gen Bank Accession No. V01555.2) (Fig. 5B). Open
reading frame translation of the canine products showed almost com-
plete identity with EBNA3C with only a single amino acid change of
isoleucine (B95-8) to valine in all three dogs (Fig. 5C). No amplicons
were identiﬁed in the other 6 dogs evaluated or in the negative
BJAB control.ISH detects EBERs in lymph nodes of dogs with spontaneous B cell
lymphoma
The use of in situ hybridization (ISH) to detect virus-speciﬁc se-
quences within lymphoid malignancies is considered the gold stan-
dard to conﬁrm that lymphoproliferative disease is associated with
EBV (Gulley and Tang, 2008). In particular, the detection of EBV-
encoded small non-polyadenylated RNAs (EBERs) by ISH is used rou-
tinely to conﬁrm EBV-associated disease. To determine whether ca-
nine B cell lymphoma is associated with an EBV-related GHV, lymph
node biopsies from 9 dogs with spontaneous DLBCL were evaluated
by ISH for the presence of EBERs (Fig. 6). Three out of 9 dogs with
DLBCL showed evidence of EBERs in malignant nodes, although the
amount of staining/hybridization varied from diffuse staining
throughout the malignant node (Fig. 6, 083-004) to staining of single
cells within sheets of neoplastic cells (Fig. 6, dog 083-16 and data not
shown). However, while the staining for EBERs in the human EBV-
associated lymphoma positive control was intense and restricted to
the nucleus (Fig. 6, positive control), staining in the canine lymph
node tissues was comparatively weak and appeared to be in the nu-
cleus and the cytoplasm. The disparity in staining may be due to dif-
ferent sequences between the human EBV-associated EBER and
canine EBER-like viral sequences leading to less intense binding and
weaker staining. Nevertheless, taken together these data suggest
that domestic dogs harbor an EBV-like GHV that may play a role in
B cell lymphomagenesis.lymphoma. A. First round PCR using degenerate primers. B. Cyclophilin PCR performed
on ﬁrst round PCR products (in A) using primers designed to amplify the canine viral
merase gene (GenBank Accession NO: V01555). E. ORF translation of nested PCR prod-
ducts and alignment with Canine Herpesvirus 1 DNA polymerase (GenBank Accession
LN, normal lymph node.
Fig. 5. Detection of EBNA3C nucleotide sequence in canine malignant lymph node tissue. A. Ampliﬁcation of EBNA3C sequence (upper panel) and control cyclophilin (lower panel)
from genomic DNA isolated from lymph node tissue of dogs with spontaneous B cell lymphoma. Genomic DNA from LCLs and BJAB cells was used as a positive and negative control
respectively. B. Nucleotide sequences of canine EBNA3C PCR amplicons and alignment to the EBNA3C coding region (partial) of EBV-1 (B95-8) (GenBank Accession No: V01555).
C. ORF translation of canine amplicons and alignment with EBNA3C protein sequence.
Fig. 6. Detection of EBERs in canine malignant lymph node tissue using in situ hybrid-
ization. Diffuse, positive staining (083-004) and single cell staining (083-016) (arrows)
is seen within sheets of neoplastic lymphocytes in the lymph nodes of two dogs with
spontaneous DLBCL. The positive control shows strong nuclear staining in an EBV-
positive human lymphoma. The negative control was performed with a scrambled
probe on an EBV-negative human lymph node.
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spontaneous DLBCL
Latent Membrane Protein-1 (LMP1) is consistently expressed in
EBV-associated lymphoproliferative malignancies where it plays an
important role in malignant transformation of lymphocytes through
its ability to up-regulate Bcl-2 and inhibit apoptosis (Henderson et
al., 1991). To determine whether this key oncogenic viral protein is
expressed in the malignant lymph nodes of dogs with DLBCL,
formalin-ﬁxed, parafﬁn-embedded lymph node sections taken from
6 dogs with DLBCL at the time of diagnosis were analyzed for LMP-1
expression by immunohistochemistry using the murine S12 antibody.
Clear cytoplasmic/membranous staining was identiﬁed in approxi-
mately 1% of the large, malignant B cells in 2 out of the 6 dogs evalu-
ated (Fig. 7A). A similar LMP-1 staining pattern was observed in
Reed–Sternberg cells within a human EBV+ HL lymph node sample
used as a positive control (Fig. 7B). Occasional plasma cells also
stained positive in canine lymph node sections although this has pre-
viously been attributed to non-speciﬁc staining. Staining of the plas-
ma cells which were charaterized morphologically by a condensed,
hyperchromatic nucleus, was predominantly perinuclear whereas ca-
nine lymphoblasts characterized morphologically by large vesicular
nuclei had distinctly more granular diffuse cytoplasmic staining. No
staining was observed in either human or canine samples using a mu-
rine IgG isotype control. To determine whether other EBV associated
proteins are expressed in malignant lymphocytes of dogs with
DLBCL, lymph node sections taken from 9 dogs were analyzed for
Fig. 8. Detection of herpesvirus particles in malignant canine B cell cultures. A. Light
microscopy of cultured malignant canine B cells (1000× magniﬁcation). B cells are
seen clustered around KtCD40L feeder cells. Arrowheads indicate mitotic ﬁgures within
a proliferating aggregate of canine B cells. Arrows indicate large (30–35 μm diameter)
irradiated KtCD40L cells undergoing degeneration characterized by cytoplasmic vacuo-
lization and blebbing, and dispersed chromatin. B. Electron microscopy of canine ma-
lignant B cells C. Electron microscopy of cultured canine B cells showing herpesvirus-
like particles. D. Viral particles present in endocytic vacuoles within malignant canine
B cells.
112 S.-H. Huang et al. / Virology 427 (2012) 107–117EBNA-1 and EBNA-2 proteins by immunohistochemistry. No staining
was identiﬁed in any of the tissue sections examined (data not
shown).
Taken together these results suggest that an LMP-1 like protein is
expressed in the lymph nodes of some dogs with DLBCL and provide a
possible mechanistic link between viral infection and lymphomagen-
esis in this species.
Identiﬁcation of herpesvirus particles in malignant canine B cell cultures
Given the identiﬁcation of viral DNA, RNA and protein in primary
malignant canine B cells we next sought to visualize assembled viral
particles in malignant canine B cell cultures. Cryopreserved, single
cell suspensions of malignant lymph nodes from 2 dogs with positive
ISH-EBER results and 1 dog with a low p18 antibody titer were
thawed and cultured with lethally irradiated KtCD40L cells as previ-
ously described for the expansion of healthy canine B cells from
PBMCs (Mason et al., 2008). Efforts to expand cryopreserved, malig-
nant canine B cells in the absence of CD40L were unsuccessful.
Short-term cultured malignant B cells were evaluated by light micros-
copy (Fig. 8A). Electron microscopy of these cultures revealed the
presence of healthy malignant B cells that could be clearly distin-
guished from the remaining, highly degenerate KtCD40L cells by
size (Fig. 8B). Particles with an electron dense central core and icosa-
hedral nucleocapsid were visualized in an extracellular location in
cultures from 1 of the EBER positive dogs (Fig. 8C), and in both
EBER positive dogs similar particles were identiﬁed in endocytic vac-
uoles (Fig. 8D). In contrast, electron microscopy of KtCD40L stimulat-
ed malignant B cells from the dog with a low VCA-p18 antibody titer
did not reveal the presence of viral particles. Taken together these re-
sults suggest that replication competent herpesvirus particles are
present in canine malignant B cell cultures and can infect canine B
cells via endocytosis, similar to EBV infection of human lymphocytes
(Nemerow and Cooper, 1984).
Discussion
Advances in the understanding of the pathogenesis of EBV and its
role in lymphomagenesis together with the development of effective
therapeutics to treat EBV-related diseases have been hampered by
the lack of spontaneous models of EBV-associated lymphoprolifera-
tive diseases. EBV naturally infects only humans and previous efforts
to understand its role in lymphomagenesis have relied upon the use
of species-speciﬁc LCV of non-human primates to approximate EBV
infection and pathogenesis. The domestic dog develops spontaneous
lymphoma that shares biological, behavioral, genetic and cytogenetic
similarities to DLBCL and Burkitt-like lymphoma subtypes in humansFig. 7. Detection of LMP-1 protein in affected lymph nodes of dogs with spontaneous
DLBCL. Formalin-ﬁxed, parafﬁn-embedded lymph node sections from A. a dog with
DLBCL and B. a human with EBV+ HL were analyzed for LMP-1 expression by immu-
nohistochemistry using the murine S12 monoclonal antibody. Results shown in A are
representative of ﬁndings from 2 dogs.and is widely recognized as a model to evaluate the safety and efﬁca-
cy of novel therapies for these disease entities in humans (Bergman et
al., 2003; Breen and Modiano, 2008; Fournel-Fleury et al., 1997; Lin et
al., 2008; MacEwen, 1990; Mason et al., 2008; Paoloni and Khanna,
2008; Paoloni et al., 2009; Thomas et al., 2003). Here we use ELISA,
ELISA blocking experiments, Western blot and IFA to show that
dogs develop speciﬁc serological responses against viral capsid anti-
gens of an EBV-like gammaherpesvirus and thus extend previous
ﬁndings of EBV-like seropositivity in dogs (Chiou et al., 2005;
Milman et al., 2011). Furthermore, for the ﬁrst time we demonstrate
the presence of viral DNA sequences and protein in the malignant
lymphocytes of dogs with spontaneous B cell lymphoma. Previous ef-
forts using PCR to identify viral sequences (BamHiW fragment) with-
in 33 canine lymphoma samples failed to identify the presence of an
EBV-like virus. In that study, a wide variety of lymphoma samples
were analyzed, including samples from skin (12), gut (5) and liver
(2). 8 malignant lymph nodes were evaluated although the pheno-
types of these malignancies were not determined. The identiﬁcation
of viral DNA sequences and the viral oncogenic protein LMP-1 in
spontaneous canine malignant B cell lymphomas outlined in this re-
port suggests for the ﬁrst time that this virus may contribute to B
cell lymphomagenesis in a subset of infected dogs. Therefore we pro-
pose that the dog may provide a unique model in which to study EBV-
related lymphomagenesis, including the genetic factors that inﬂuence
its development and novel therapies that may treat or prevent EBV-
related disease.
In humans, infection with EBV is marked by an early and persis-
tent IgG antibody response directed against the highly immunogenic,
lytic phase small VCAs p18 and p23 (van Grunsven et al., 1993a;
Hinderer et al., 1999). IgG titers against these lytic antigens are ex-
tremely robust, minimally affected by immune suppression and per-
sist for the lifetime of the individual (Klutts et al., 2009). As such,
their identiﬁcation is used routinely to conﬁrm infection with EBV
in humans (reviewed in Pattle and Farrell, 2006). Likewise, the
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conﬁrm infection with closely related LCVs that express homologs
of EBV-VCA p18 and p23 in the rhesus monkey and common marmo-
set (Jiang et al., 2000; Moghaddam et al., 1998). Homologs of EBV-
VCA p18 and p23 have also been identiﬁed in the rhadinovirus Bovine
Herpes Virus 4 (BHV4) (NP 076557.1). In this report, we show for the
ﬁrst time that domestic dogs have serological IgG responses that cross
react with both EBV-VCA-p18 and EBV-VCA-p23. Since dogs without
lymphoma have detectable serological responses, our ﬁndings sug-
gest that as with EBV infection in humans, infection with an EBV-
like virus in dogs is likely asymptomatic in many cases. Importantly
as there are no closely related homologs of VCA p18 or p23 in alpha-
herpesviruses (including the only known canine alphaherpesvirus
CHV-1) or betaherpesviruses, these serological ﬁndings suggest that
privately owned dogs have been naturally exposed to an EBV-like
GHV.
Although serological responses against EBV-speciﬁc thymidine ki-
nase, EBV encoded DNA binding protein, EBV-speciﬁc DNA polymer-
ase and LCLs have been reported in healthy pet dogs suggesting the
presence of an asymptomatic GHV carrier state (Chiou et al., 2005;
Milman et al., 2011) an association between viral infection and lym-
phomagenesis in the dog has not been identiﬁed. Here we show
that dogs with the highest anti-VCA antibody titers have spontaneous
B cell lymphoma. In humans, serological antibody titers against VCA
remain relatively constant over the lifetime of the individual (Khan
et al., 1996). Increases in anti-VCA titer reﬂect active viral replication
and high anti-VCA titers have been identiﬁed in patients with EBV-
associated lymphoproliferative disorders including Hodgkin's lym-
phoma, BL and PTLD (Fan et al., 2005; Gallagher et al., 1999; Khan
et al., 2005; Riddler et al., 1994). Previous retrospective studies have
shown that high anti-VCA titers and viral loads may be predictive of
lymphomagenesis in human patients (de-The et al., 1978; Mueller
et al., 1989). Given that certain breeds of dog, such as the Golden Re-
triever, have a very high lifetime risk of developing lymphoma (1 in
8 dogs) (Glickman L, 2000), identiﬁcation of an EBV-like virus that
contributes to canine lymphomagenesis provides a unique opportuni-
ty to prospectively evaluate whether increasing anti-VCA antibody ti-
ters predict onset of lymphomagenesis in a genetically predisposed
group of dogs.
Conﬁrmation of the association between EBV infection and tumor-
igenesis is based in large part on demonstration of viral proteins and/
or viral nucleotide sequences within malignant cells (Weiss et al.,
1991; Wu et al., 1990). As EBERs are expressed in all stages of viral la-
tency, their identiﬁcation in biopsy specimens using ISH represents
the gold standard for identifying latent EBV infection and demon-
strating an association between infection and tumorigenesis (Gulley
and Tang, 2008). Our EBER-ISH ﬁndings are consistant with those
reported in human patients with B-NHL. Several reports indicate
that between 4% and 7% of B-NHL cases are EBV positive as demon-
strated by EBER-ISH (d'Amore et al., 1996; Ohshima et al., 1990). Fur-
thermore signiﬁcant heterogeneity in EBER staining patterns occur
among individuals with B-NHL (d'Amore et al., 1996). The vast major-
ity of EBER positive B-NHL cases contained only a few scattered EBER-
positive cells (19/25) whereas 4/25 and 2/25 had intermediate and
extensive positivity respectively (d'Amore et al., 1996). In contrast,
in human tumors such as EBV associated Burkitt lymphoma (positive
EBER-ISH control) and post transplant lymphoproliferative disease,
virtually all the tumor cells are EBER positive. IHC to identify LMP-1
is also used to conﬁrm the presence of latent infected B cells in lym-
phoid malignancies (Pallesen et al., 1991; Young and Murray, 2003).
Here we demonstrate the presence of nucleotide sequences that are
highly similar to EBERs, EBV DNA polymerase and EBNA3C together
with proteins that cross react with an anti-LMP-1 antibody (suggest-
ing high similarity to LMP-1) within the malignant lymph nodes of a
subset of dogs with DLBCL. The high level of nucleotide sequence ho-
mology between canine viral sequences and EBV type I suggests thatthese dogs are infected with EBV or a highly homologous EBV-like
virus. Future deep sequencing of the canine virus will allow for this
distinction to be made. Importantly, the difference in nucleotide se-
quence of the DNA polymerase gene makes it unlikely that our ﬁnd-
ings are due to contamination with laboratory strains of EBV.
Although the function of EBERs is unknown, LMP-1 plays an im-
portant role in lymphocyte transformation by driving the lympho-
cyte cell cycle and inhibiting apoptotic pathways through over-
expression of Bcl-2 (Henderson et al., 1991). Our ﬁndings of an as-
sociation of LMP-1 with canine malignant lymphocytes is consistent
with our hypothesis that a naturally occurring EBV-like herpesvirus
may contribute to lymphomagenesis in this species. Interestingly,
the frequency of LMP-1 positive malignant cells in the canine tissue
samples was very low and more consistent with ﬁndings in NHL of
immune competent humans (Jiwa et al., 1995). This is in contrast
to Hodgkin's lymphoma where the frequency of LMP-1 positive
Reed–Sternberg cells varies between 10% and 80%. The low fre-
quency of LMP-1 stained cells in canine NHL tissue samples may
be associated with targeted immunological destruction of LMP-1
positive cells, suppression of LMP-1 expression or decreased detec-
tion of a canine homolog by the S12 antibody. Likewise, failure to
identify EBNA-1 or EBNA-2 staining in canine DLBCL samples may
be associated with failure of the antibody to cross react with a pu-
tative canine GHV, or a stage of latency where EBNA-1/2 is not
expressed. Future studies correlating EBER ISH with LMP-1 expres-
sion in canine malignant tissue samples may provide important in-
sights into the clinical relevance of EBV-like infection and LMP-1
expression in this spontaneous dog model.
Our electron microscopy ﬁndings suggest that infectious, replica-
tion competent viral particles are present in malignant canine B cell
cultures. While these cells are grown in the presence of human
KtCD40L cells, these feeder cells do not express CD21, are lethally ir-
radiated prior to use and repeatedly test negative for EBV DNA by
PCR. Furthermore, we did not detect the presence of viral particles
in a third KtCD40L-stimulated B cell culture using malignant lympho-
cytes from a dog with a low VCA-p18 titer. As such, it is extremely un-
likely that visualized viral particles derive from the KtCD40L cells. The
observation of intact viral particles within endocytic vacuoles of cul-
tured canine B cells is highly reminiscent of the initial stages of EBV
infection of human B cells and suggests that the virus present in
these cultures can infect canine B cells in vitro. However, in the ab-
sence of immunoelectron microscopy, the identiﬁcation of these
viral particles as EBV or EBV-like cannot be conﬁrmed. The generation
of spontaneous canine LCLs from primary tumor specimens in the ab-
sence of feeder cells has generally been unsuccessful and only a few
canine B cell lines are available. This may reﬂect a low incidence of
GHV-associated lymphomagenesis in the dog or sub-optimal culture
methods for LCL generation. Although LMP-1 expression mimics
CD40 signaling and should intrinsically enable LCL production, re-
combinant canine IL-4 and CD40-CD40L signaling appears to be re-
quired for canine malignant B cell growth and culture. It should be
noted that cyclosporine is used in these cultures to suppress T cell ac-
tivation and proliferation; this is important since CD40L-treatment of
EBV infected cells increases their sensitivity to CD8 T cell mediated
lysis (Gulley and Tang, 2008). Nevertheless, the identiﬁcation of
KtCD40L feeder cells as an efﬁcient system for canine malignant B
cell culture should now enable this herpesvirus to be cultured, isolat-
ed and fully characterized.
There are a number of reports of interspecies herpesvirus trans-
mission including transmission of the pseudorabies virus, suis her-
pesvirus 1 from pigs to dogs. However, currently LCVs are thought
to be restricted to humans and non-human primates. Given the
close contact between humans and dogs during the last
15,000 years of domestication, and recent evidence that traces the or-
igins of EBV back to over 5 million years ago it is possible that inter-
species transmission has occurred and a novel, closely related EBV-
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Future deep sequencing of this canine virus will provide important
insight into the phylogeny and epidemiology of this virus.
Conclusions
The ﬁndings reported here of high antibody titers to EBV-VCA p18
and p23 in dogs with spontaneous B cell lymphoma and EBV-related
viral components within the malignant lymph nodes have important
implications for both the human and veterinary medical ﬁelds and
raise the intriguing possibility that the long sought after spontaneous
model for EBV-associated lymphomagenesis might reside in man's
best friend, his dog.
Methods
Cells, cell lines, animals and reagents
Canine peripheral blood mononuclear cells (PBMCs) were isolated
by Ficoll density gradient centrifugation. Primary malignant canine B
cells were obtained from the lymph nodes of dogs with untreated
NHL after owner's informed consent and with approval from the Uni-
versity of Pennsylvania's Institutional Animal Care and Use Commit-
tee. The human EBV positive lymphoblastoid cell lines (LCLs) and
the EBV-negative cell lines B-JAB were grown in standard RPMI
media containing 10% FCS and 100 mg/ml of Penicillin and Strepto-
mycin as previously described (Menezes et al., 1975; Rutgen et al.).
Genomic DNA was extracted using the DNeasy kit (Qiagen). Archived
canine plasma samples and tissue samples were obtained from the
University of Pennsylvania's Tumor Tissue Bank and from speciﬁc
pathogen free (SPF) Beagles at Liberty Research, Inc. (Waverly, NY).
Recombinant EBV proteins p18-VCA and p23-VCA were obtained
from GenWay Biotech Inc. (San Diego, CA).
ELISA and end point dilution titers
ELISA plates (MaxiSorb Nunc) were coated with 0.5μg of either re-
combinant p18-VCA protein or p23-VCA protein (GenWay Biotech
Inc.) in PBS at 4 °C overnight. Plates were blocked with 3% BSA in
PBS for 1 hour at 37 °C. Canine plasma samples were diluted 1:21 in
3% BSA in PBS and incubated on the plates for 2 hours at 37 °C. Plates
were washed seven times with 1× PBST. Bound antibody was
detected using Horseradish peroxidase-conjugated AfﬁniPure rabbit
anti-human or rabbit anti-dog IgG (H+L) (1:50,000 dilution in 5%
milk/PBS, Jackson ImmunoResearch Laboratories Inc., West Grove,
PA). Plates were washed seven times and developed using 3,3,5,5-tet-
ramethylbenzidine (TMB) peroxidase substrate (Kinkergaard and
Perry Laboratories, Gaithersburg, MD, USA). Optical density (OD)
was read at 650 nm after 30 min using a Spectraﬂuor Plus® spectro-
photometer (Tecan US, Inc. Mannedorf, Switzerland). Commercially
available standard human positive and negative controls were includ-
ed on each plate (Calbiotech Inc., Spring Valley, CA.). For antigen
blocking experiments, 1:21 dilutions of plasma were incubated with
8μg of either p18-VCA or p23-VCA for 1 hour at 37 °C, prior to per-
forming ELISA. To account for inter-plate variability, all samples
O.D.s were expressed as a ratio relative to the O.D. of the human neg-
ative control. All samples were run in duplicate. For end point dilution
titers, serial 1:2 dilutions of all samples were made in 3% BSA in PBS
up to 1:32,768 and ELISA was performed as above. The end point di-
lution titer was deﬁned as the reciprocal of the last sample dilution
that gave a positive reading above three times the background O.D.
Western blot
1 μg of recombinant p23-VCA protein was subject to electrophore-
sis on a 10% polyacrylamide gel and transferred to a PVDF membrane(Bio-Rad, Hercules, CA, USA). The membrane was blocked with 5%
milk in TBST with 1% rabbit serum for 1 hour at room temperature.
Canine plasma samples were diluted 1:100 in blocking buffer and in-
cubated with the PVDF membrane overnight at 4 °C. Membranes
were then washed 3 times with 1× TBST and incubated for 1 hour
with a 1:50,000 dilution of HRP conjugated rabbit anti-dog IgG or rab-
bit anti-human IgG antibody (Jackson ImmunoResearch) in blocking
buffer at room temperature. Membranes were then washed 3 times
with 1× TBST and blots were developed using ECL Plus (Amersham
Biosciences, Piscataway, NJ, USA). Human EBV-positive plasma and
a commercially available human standard negative control (Calbio-
tech Inc.) were used as positive and negative controls respectively.
Polymerase chain reactions
For degenerate DNA Polymerase PCR reactions, total RNA was
extracted from the lymph nodes of healthy dogs and dogs with
DLBCL using the RNeasy Mini Kit (Qiagen). Reverse transcription
was performed using random hexamers and Superscript II reverse
transcriptase (Invitrogen Corp, Carlsbad. CA, USA) according to the
manufacturer's instructions. PCR was performed using degenerate
primers and cycling conditions previously described to amplify the
highly conserved region of herpesvirus DNA polymerase (Rose et al.,
1997). Nested primers were designed based on the canine DNA poly-
merase sequence as follows: sense: 5′-GGGGTGGCCAACGGCCTCTTT-
3′; anti-sense: 5′-TMMTYCGTAGCTGACTCGGGTGA-3′. PCR was per-
formed using 2 μl of the ﬁrst round PCR reaction; 0.5U Vent DNA po-
lymerase, 0.4 mM dNTP, 0.4 μM primers and 1× Thermo buffer in a
50 μl reaction volume. Cycling conditions used to amplify the canine
speciﬁc sequence were as follows: 94 °C for 3 min; 94 °C for 20 sec,
60 °C for 20 sec, 72 °C for 45 sec (42 cycles); 72 °C for 10 min.
For EBNA3C PCR, genomic DNA was isolated from the malignant
lymphocytes of dogs with DLBCL and from LCL-1 cells (positive con-
trol) and BJAB cells (negative control) using the QIAamp DNA Mini
kit (Qiagen). PCR was performed using 200 ng of genomic DNA and
primers previously described (Moon et al., 2004). Cycling conditions
were as follows: 94 °C for 5 min; 94 °C for 10 sec, 58 °C for 5 sec,
72 °C for 10 sec (35 cycles); 72 °C for 5 min. Ampliﬁcation of canine
cyclophilin was used as an internal control and was performed
using primers and cycling conditions previously described
(Campbell et al., 2001).
Immunohistochemistry
Immunohistochemical analysis for LMP-1, EBNA-1 and EBNA-2
was performed on formalin ﬁxed, parafﬁn-embedded tissue sections
of lymph nodes from healthy dogs and dogs with DLBCL. A human
EBV+ HL section was used as a positive control. Sections were depar-
afﬁnized in xylene and rehydrated through graded alcohols to dis-
tilled water. Sections were subjected to heat-induced epitope
retrieval by boiling the slides in 0.1 M citrate buffer (pH 6.0) for
10 mins. Endogenous peroxidase was blocked with 0.3% hydrogen
peroxide in methanol for 10 min. Slides were incubated with a mu-
rine anti-LMP-1 monoclonal antibody (S12) (Mann et al., 1985;
Rowe, 2001) at room temperature for 1 hour, followed by a 1:100 di-
lution of biotinylated horse anti-mouse IgG (Vector Labs, Burlingame,
CA) at room temperature for 30 min. For EBNA-1 and EBNA-2 stain-
ing, slides were incubated with either a rabbit polyclonal anti-
EBNA-1 antibody (a kind gift from Dr. Paul Lieberman) (1:250 dilu-
tion) or a mouse polyclonal anti-EBNA-2 antibody (1:300 dilution)
at room temperature for one hour, followed by a 1:100 dilution of
biotinylated horse anti-mouse/anti-rabbit IgG at room temperature
for 30 min. In all cases, bound antibody was detected using the
streptavidin-biotin-peroxidase ABC method (Vector Labs) as per the
manufacturer's instructions using 3′,3′ diaminobinzidine (DAB) as
chromagen (Invitrogen). Tissue sections were counterstained with
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xylene prior to mounting with Histomount (Invitrogen).Indirect immunoﬂuorescence
The commercially available EBV-VCA IgG immunoﬂuorescence
assay (IFA) (Fuller Laboratories, Fullerton, CA) based on chemically
induced, acetone ﬁxed P3HR-1 human lymphoblastoid cells that ex-
press the full range of EBV early and late antigens was modiﬁed to de-
tect canine IgG. Brieﬂy, canine plasma was diluted 1:10 in PBS and
10 μl of sample was added to lymphoblastoid cells on IHC slides for
30 mins at 37 °C. Slides were rinsed three times with PBS and incu-
bated with a FITC conjugated rabbit anti-canine IgG antibody
(1:1600 dilution; Jackson Immunoresearch) for 30 mins at 37 °C.
Slides were rinsed again and visualized using a Nikon E600 Inﬁnity
corrected upright microscope. Images were captured with a Nikon
Digital Sight DS-Fi1 Color camera using NIS-Element BR3.0 software.EBER in situ hybridization
ISH was performed on a Ventana XT (http://www.ventanamed.
com/product/page?view=benchmarkxt) sytem using the iVIEW
Blue detection system (http://www.ventanamed.com/product/list/
12) using the Ventana EBER DNP RNA Probe according to the manu-
facturer's instructions.Electron microscopy
Cryopreserved malignant lymphocytes were thawed and cultured
with lethally irradiated K562 cells transfected with human CD40L
(KtCD40L) at a ratio of 5:1 in the presence of recombinant canine
IL-4 (R&D Systems, Minneapolis, MN) and cyclosporine as previously
described (Mason et al., 2008). Cells were re-stimulated every
5–7 days with fresh, lethally irradiated KtCD40L. Four days following
the third round of stimulation, cells were harvested and evaluated by
light microscopy. For electron microscopy cells were ﬁxed in 2.5% glu-
taraldehyde and 2.0% paraformaldehyde. Samples were post ﬁxed in
osmium tetroxide, washed and stained with 2% aqueous uranyl ace-
tate. Cells were rinsed in distilled water, dehydrated and embedded
in Embed 812 (Electron Microscopy Science, Fort Washington, PA).
Sections were examined using a JEOL 100CX electron microscope
and digital images were recorded using a Hamamatsu camera.AbbreviationsBL Burkitt's Lymphoma
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